Tags

Type your tag names separated by a space and hit enter

Legionnaires' disease: clinical, epidemiological, and public health perspectives.
Semin Respir Infect. 1998 Jun; 13(2):84-9.SR

Abstract

Legionnaires' disease is a modern environmental infectious disease. It stems from the capacity of the causative agent, Legionella, to multiply within amoebae in warm water and the use, during the 20th century, of devices that maintain water at warm temperatures and produce aerosols. When contaminated with Legionella, aerosols consisting of respirable droplets place the bacteria in juxtaposition with alveolar macrophages, which, as with amoebae, they may parasitize, resulting in illness in susceptible persons. The disease is much more common than previously appreciated with at least 13,000 cases estimated to occur per year in the United States, based on prospective studies. Two highly specific tests, urinary antigen detection and sputum culture, are available for diagnosis during illness. With 60% to 80% sensitivity, urinary antigen tests rapidly detect antigens of Legionella pneumophila serogroup 1, which are responsible for 70% of the cases of legionnaires' disease; results can be available within a few hours. Culture of sputum is 50% to 60% sensitive, but several days are required for growth, and many patients do not produce sputum. Serologic testing, although useful for epidemiologic studies when convalescent-phase antibody titers can be compared with acute-phase titers, is not helpful for clinical decision making because of the low positive predictive value of commercially available acute-phase serologic tests. Erythromycins, intravenous azithromycin, and levofloxacin are currently approved by the US Food and Drug Administration for treatment of legionnaires' disease. However, clarithromycin and several other fluoroquinolones are active against Legionella and may also provide effective therapy. Recent recommendations from the Centers for Disease Control and Prevention's Hospital Infection Control Practices Advisory Committee should be helpful in reducing nosocomial legionnaires' disease. Recommendations are in place or are being developed to minimize the risk of disease in a variety of other settings.

Authors+Show Affiliations

Division of Bacterial and Mycotic Diseases, National Center for Infectious Diseases, Centers for Disease Control and Prevention, Atlanta, GA 30333, USA.No affiliation info available

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

9643385

Citation

Breiman, R F., and J C. Butler. "Legionnaires' Disease: Clinical, Epidemiological, and Public Health Perspectives." Seminars in Respiratory Infections, vol. 13, no. 2, 1998, pp. 84-9.
Breiman RF, Butler JC. Legionnaires' disease: clinical, epidemiological, and public health perspectives. Semin Respir Infect. 1998;13(2):84-9.
Breiman, R. F., & Butler, J. C. (1998). Legionnaires' disease: clinical, epidemiological, and public health perspectives. Seminars in Respiratory Infections, 13(2), 84-9.
Breiman RF, Butler JC. Legionnaires' Disease: Clinical, Epidemiological, and Public Health Perspectives. Semin Respir Infect. 1998;13(2):84-9. PubMed PMID: 9643385.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Legionnaires' disease: clinical, epidemiological, and public health perspectives. AU - Breiman,R F, AU - Butler,J C, PY - 1998/6/27/pubmed PY - 1998/6/27/medline PY - 1998/6/27/entrez SP - 84 EP - 9 JF - Seminars in respiratory infections JO - Semin Respir Infect VL - 13 IS - 2 N2 - Legionnaires' disease is a modern environmental infectious disease. It stems from the capacity of the causative agent, Legionella, to multiply within amoebae in warm water and the use, during the 20th century, of devices that maintain water at warm temperatures and produce aerosols. When contaminated with Legionella, aerosols consisting of respirable droplets place the bacteria in juxtaposition with alveolar macrophages, which, as with amoebae, they may parasitize, resulting in illness in susceptible persons. The disease is much more common than previously appreciated with at least 13,000 cases estimated to occur per year in the United States, based on prospective studies. Two highly specific tests, urinary antigen detection and sputum culture, are available for diagnosis during illness. With 60% to 80% sensitivity, urinary antigen tests rapidly detect antigens of Legionella pneumophila serogroup 1, which are responsible for 70% of the cases of legionnaires' disease; results can be available within a few hours. Culture of sputum is 50% to 60% sensitive, but several days are required for growth, and many patients do not produce sputum. Serologic testing, although useful for epidemiologic studies when convalescent-phase antibody titers can be compared with acute-phase titers, is not helpful for clinical decision making because of the low positive predictive value of commercially available acute-phase serologic tests. Erythromycins, intravenous azithromycin, and levofloxacin are currently approved by the US Food and Drug Administration for treatment of legionnaires' disease. However, clarithromycin and several other fluoroquinolones are active against Legionella and may also provide effective therapy. Recent recommendations from the Centers for Disease Control and Prevention's Hospital Infection Control Practices Advisory Committee should be helpful in reducing nosocomial legionnaires' disease. Recommendations are in place or are being developed to minimize the risk of disease in a variety of other settings. SN - 0882-0546 UR - https://www.unboundmedicine.com/medline/citation/9643385/Legionnaires'_disease:_clinical_epidemiological_and_public_health_perspectives_ L2 - https://medlineplus.gov/legionnairesdisease.html DB - PRIME DP - Unbound Medicine ER -